Novo Nordisk (NVO) and Eli Lilly (LLY) have negotiated to reduce the price of their GLP-1 weight loss drugs and ...

Hims & Hers Health ($HIMS) stock has been a wild ride lately, as investors struggle to decide whether it’s the future of ...

Hims & Hers Health Inc (NYSE: HIMS) isn't just chasing wellness trends — it's building a global health platform. At the ...

Syndax Pharmaceuticals Inc. SNDX) on Monday reported a loss of $60.7 million in its third quarter. The New York-based company said it had a loss of 70 cents per share.

Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2025, in a ...

Hims & Hers Health HIMS-1.04%decrease; red down pointing triangle said it is now providing menopause care, marking the company’s latest push into hormone-replacement therapies. The telehealth company ...

The latest strand in Pelage Pharmaceuticals’ growing funds comes from a $120 million series B fundraising round that the biotech plans to apply to its regenerative hair loss treatment. Arch Venture ...

Finasteride, a common hair-loss drug, has long been tied to depression and suicide, but regulators ignored the warnings. Prof. Mayer Brezis’s review exposes global data showing psychiatric harm and a ...

This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255). Millions of men undergoing hair ...

We recently published 10 Hot Stocks Sparking Buying Frenzy. Hims & Hers Health Inc. (NYSE:HIMS) is one of the best performers on Tuesday. Hims & Hers rallied for a second day on Tuesday, adding 5.86 ...

Androgenetic alopecia is a common form of hair loss in both men and women—also called male pattern baldness and female pattern hair loss. Topical minoxidil is an approved treatment, but it has poor ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...